| 7.9 0.4 (5.33%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.54 |
1-year : | 11.15 |
| Resists | First : | 8.17 |
Second : | 9.54 |
| Pivot price | 7.34 |
|||
| Supports | First : | 7.13 |
Second : | 6.48 |
| MAs | MA(5) : | 7.66 |
MA(20) : | 7.24 |
| MA(100) : | 6.26 |
MA(250) : | 4.55 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 90.2 |
D(3) : | 89.6 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 9.42 | Low : | 2.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRVI ] has closed below upper band by 10.9%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.92 - 7.96 | 7.96 - 7.98 |
| Low: | 7.44 - 7.47 | 7.47 - 7.51 |
| Close: | 7.83 - 7.9 | 7.9 - 7.95 |
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Fri, 02 Oct 2026
MILLENNIUM MANAGEMENT LLC Adds Maravai LifeSciences Holdings Inc - GuruFocus
Thu, 01 Oct 2026
Form 4 Maravai Lifesciences Holdings Inc For: 1 October By Investing.com - Investing.com India
Tue, 29 Sep 2026
More than 5% of Maravai LifeSciences (MRVI) shares are listed with shared voting power. - stocktitan.net
Fri, 25 Sep 2026
Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers? - Yahoo Finance
Thu, 24 Sep 2026
Is Maravai LifeSciences Holdings (MRVI) Cheap After Its Recovery Narrative Pushed Shares To $7.37? - Simply Wall Street
Thu, 24 Sep 2026
Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 9,380 (K) |
| Shares Short P.Month | 9,270 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | -37.1 % |
| Operating Margin | -29.4 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -33.1 % |
| Qtrly Rev. Growth | 8.5 % |
| Gross Profit (p.s.) | 0.5 |
| Sales Per Share | 1.4 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -14.91 |
| PEG Ratio | 0 |
| Price to Book value | 5.76 |
| Price to Sales | 5.63 |
| Price to Cash Flow | -46.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|